AIDS News and Research

RSS

U.S. will strengthen health work in Haiti

In a post on the AIDS.gov blog, Ambassador Eric Goosby, U.S. global AIDS coordinator, writes about a recent visit to Haiti and gives an update on U.S. work with Haiti.

16 Jul 2011

Lancet issue dedicated to HIV/AIDS ahead of IAS conference

The current issue of the Lancet is dedicated to HIV/AIDS, a theme meant to coincide with the sixth International AIDS Society (IAS) conference on HIV pathogenesis, treatment and prevention taking place in Rome, Italy, July 17-20, according to a Lancet article.

16 Jul 2011

Study finds structural determinants of adolescent girls' vulnerability to HIV

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health shows that community members correlate an increase in HIV vulnerability among adolescent girls with weak structural support systems.

14 Jul 2011

Two new studies support use of PrEP for HIV prevention among heterosexual men and women

"Two new studies done in three African countries have shown for the first time that AIDS drugs taken daily can cut by more than half a person's chance of becoming infected with HIV through heterosexual intercourse," the Washington Post reports.

14 Jul 2011

Studies show AIDS drugs can prevent heterosexuals from acquiring HIV

Two new studies released early Wednesday show that AIDS drugs can prevent heterosexuals from acquiring HIV, adding to a growing number of new methods to slow the spread of the virus world-wide.

14 Jul 2011

Five-year research initiative to cure HIV disease

A team of AIDS experts at Johns Hopkins and other institutions have embarked on a joint five-year research initiative to cure HIV disease by finding ways to completely purge the virus from the body in people already successfully suppressing the virus with antiretroviral drug therapy.

14 Jul 2011

Daily pill ‘combo’ prevents HIV transmission: New African study

According two studies in Africa, taking a daily pill containing either one or two anti-HIV drugs can reduce transmission of the virus by as much as three-quarters among heterosexual couples. This is an encouraging finding that could help focus on AIDS prevention. The results were so compelling that the larger study was halted early and the drugs given to all the participants, researchers said Wednesday.

13 Jul 2011

First Edition: July 13, 2011

Today's headlines detail the next moves in the ongoing budget discussion, including a "last-choice option" proposed by Senate Minority Leader Mitch McConnell, R-Ky., and reports about how the health industry is lining up against possible cuts.

13 Jul 2011

AIDS activists and advocates to protest against Gilead's drug pricing at San Francisco federal building

A small group of committed AIDS activists and advocates spearheaded by AIDS Healthcare Foundation (AHF) will protest the Bay Area's own Gilead Sciences over its pricing and policies on its HIV/AIDS medications.

13 Jul 2011

IAS, NIDA announce recipients of third annual joint research fellowships

The International AIDS Society (IAS) and the US National Institute on Drug Abuse (NIDA) today announced the recipients of their third annual joint research fellowships. Recipients of the prestigious awards will receive US$75,000 each to advance scientific understanding of the linkages between drug use and HIV while fostering multinational research.

13 Jul 2011

NIH grants $70M over five years to help search for HIV cure

NIH announced on Monday it will provide $70 million over five years to three collaborations searching for an HIV/AIDS cure, making it "the largest single investment yet … into finding a way to rid the virus from the body or at least reduce levels to the point that infected people can stop taking anti-HIV drugs - which many researchers until recently viewed as a hopeless quest," ScienceInsider reports.

13 Jul 2011

AHF applauds Gilead for licensing AIDS drugs to Medicines Patent Pool

AIDS Healthcare Foundation (AHF) today lauded Gilead Sciences for being the first major AIDS drug company to share some drug patents with a new international Medicines Patent Pool, a move that will help ensure access to newer AIDS treatments in developing countries.

13 Jul 2011

Gilead becomes first company to license drugs to Medicines Patent Pool

"In the first agreement between a pharmaceutical company and the new international Medicines Patent Pool, Gilead Sciences announced Tuesday that it would license four of its AIDS and hepatitis B drugs to the pool," the New York Times reports.

13 Jul 2011

Donors should continue to provide AIDS funding to China, UNAIDS head says

Cutting AIDS funding to China will "be a big mistake for a donor and particularly, for anyone who's invested in China today, ... for the simple reason that this funding is a catalytic fund," UNAIDS Executive Director Michel Sidibe told Reuters in an interview on Monday.

13 Jul 2011

Sexually transmitted diseases more common in women age 40

A Johns Hopkins infectious disease expert is calling for all sexually active American women age 40 and older to get tested for the parasite Trichomonas vaginalis after new study evidence found that the sexually transmitted disease (STD) is more than twice as common in this age group than previously thought.

12 Jul 2011

Gilead, Mylan expand license deal for HIV/AIDS medicines

Mylan Inc. today announced an expanded licensing agreement between Gilead Sciences Inc. and Mylan's Matrix Laboratories Limited.

12 Jul 2011

UNC receives $32 million federal grant to eradicate HIV infection

Researchers at the University of North Carolina at Chapel Hill have been awarded a $32 million, five-year federal grant to develop ways to cure people with HIV by purging the virus hiding in the immune systems of patients taking antiretroviral therapy.

12 Jul 2011

New research strategy for eradicating HIV from the body

An international team led by researchers from the University of California, San Francisco and the nonprofit Vaccine and Gene Therapy Institute of Port St. Lucie, Fla., has received a major grant from the National Institutes of Health to develop a strategy to eradicate HIV from the body.

12 Jul 2011

Merck researchers to participate in two new collaborative efforts to study HIV latency

Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.

12 Jul 2011

Gilead announces expansion of global access program for HIV medications

Gilead Sciences, Inc. announced today an expansion of its global access program in an effort to provide accelerated access to Gilead medicines for the treatment of HIV/AIDS.

12 Jul 2011